Financial reports
Current reports
8-K
Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
7 May 24
8-K
Other Events
15 Apr 24
8-K
Neumora Therapeutics Reports Fourth Quarter and Full Year 2023
7 Mar 24
8-K
Regulation FD Disclosure
8 Jan 24
8-K
Other Events
28 Nov 23
8-K
Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
1 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
19 Sep 23
Registration and prospectus
S-8
Registration of securities for employees
7 Mar 24
S-8
Registration of securities for employees
19 Sep 23
424B4
Prospectus supplement with pricing info
18 Sep 23
8-A12B
Registration of securities on exchange
13 Sep 23
S-1/A
IPO registration (amended)
11 Sep 23
S-1
IPO registration
25 Aug 23
DRS/A
Draft registration statement (amended)
9 Aug 23
DRSLTR
Correspondence regarding draft registration statement
8 Aug 23
DRS/A
Draft registration statement (amended)
30 Jun 23
DRSLTR
Correspondence regarding draft registration statement
30 Jun 23
Other
EFFECT
Notice of effectiveness
18 Sep 23
CERT
Certification of approval for exchange listing
14 Sep 23
SEC STAFF LETTER
SEC staff letter
14 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
12 Sep 23
CORRESP
Correspondence with SEC
25 Aug 23
UPLOAD
Letter from SEC
17 Aug 23
UPLOAD
Letter from SEC
12 Jul 23
SEC STAFF LETTER
SEC staff letter
24 May 23
UPLOAD
Letter from SEC
24 May 23
Ownership